Log in

Start Your Membership Now

July 29, 2009 On July 28, 2009, the California legislature amended the Lanterman Act which governs developmental disability support services; the amendment was in budget legislation called the Trailer Bill. The California Department of Developmental Services (DDS) sent a letter to the regional center directors and boards to advise them about Trailer Bill language affecting the regional centers. Specifically, DDS highlighted the types of treatments and programs that could be considered experimental, including experimental medical or nutritional therapy when the use of the product for that purpose is not a general physician practice. DSS did not define the level of . . .

Want To Read More? Log In Or Become A Paid Member
Resource Available For Paid OPEN MINDS Circle Members Only
Not a paid member? Don't miss out! Sign up today and receive unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!
Log In
If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

Become A Paid Member
If you are not yet a paid member, learn more about the OPEN MINDS Circle Market Intelligence Service Membership on our website, reach out to our team at info@openminds.com, or call us at 877-350-6463.

Market Intelligence Resource | July 29, 2009

California Department of Developmental Services Letter to Regional Center Directors & Board Presidents About Trailer Bill Language Affecting Regional Centers

July 29, 2009 On July 28, 2009, the California legislature amended the Lanterman Act which governs developmental disability support services; the amendment was in budget legislation called the Trailer Bill. The California Department of Developmental Services (DDS) sent a letter to the regional center directors and boards to advise them about Trailer Bill language affecting the regional centers. Specifically, DDS highlighted the types of treatments and programs that could be considered experimental, including experimental medical or nutritional therapy when the use of the product for that purpose is not a general physician practice. DSS did not define the level of . . .

Want To Read More? Log In Or Become A Paid Member
Resource Available For Paid OPEN MINDS Circle Members Only
Not a paid member? Don't miss out! Sign up today and receive unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!
Log In
If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

Become A Paid Member
If you are not yet a paid member, learn more about the OPEN MINDS Circle Market Intelligence Service Membership on our website, reach out to our team at info@openminds.com, or call us at 877-350-6463.